ASH 2024 Highlights: GMMG-HD7 Study

Opinion
Video

Panelists discuss how recent findings from the GMMG-HD7 trial comparing isatuximab-RVd vs RVd have shaped treatment decision-making in patients with multiple myeloma by providing comparative efficacy and safety data between the 2 regimens.

Video content above is prompted by the following:

  1. How have the latest data informed your treatment decision?
    1. GMMG-HD7, Isa-RVd vs RVd
Recent Videos
3 experts are featured in this series.
3 experts are featured in this series.
Related Content
Having extramedullary disease correlated with worse PFS and OS among patients who received belantamab mafodotin for relapsed/refractory multiple myeloma.

Belantamab Mafodotin Shows Real-World Efficacy in Pretreated R/R Myeloma

Russ Conroy
January 29th 2025
Article

Having extramedullary disease correlated with worse PFS and OS among patients who received belantamab mafodotin for relapsed/refractory multiple myeloma.

Samantha Shenoy, NP, MSN, discusses how her role plays a vital part in patient care for those receiving talquetamab for multiple myeloma.

Mitigating AEs and Protecting QOL Following Talquetamab in Multiple Myeloma

Samantha Shenoy, NP, MSN
October 14th 2024
Podcast

Samantha Shenoy, NP, MSN, discusses how her role plays a vital part in patient care for those receiving talquetamab for multiple myeloma.

Isatuximab Combo Approved in EU for Transplant-Ineligible NDMM

Isatuximab Combo Approved in EU for Transplant-Ineligible NDMM

Tim Cortese
January 22nd 2025
Article

Patients who received the isatuximab combination in the IMROZ trial experienced prolonged MRD-negativity, which correlated with improved PFS.

James R. Berenson, MD, describes ongoing efforts to evaluate treatment with JAK inhibitors like ruxolitinib among patients with multiple myeloma.

Exploring the Potential Role of JAK Inhibitors in Multiple Myeloma

James R. Berenson, MD, FACP
September 30th 2024
Podcast

James R. Berenson, MD, describes ongoing efforts to evaluate treatment with JAK inhibitors like ruxolitinib among patients with multiple myeloma.

Subcutaneous Isatuximab Shows Noninferior ORR, C Trough in R/R Myeloma

Subcutaneous Isatuximab Shows Noninferior ORR, C Trough in R/R Myeloma

Tim Cortese
January 9th 2025
Article

Subcutaneous isatuximab yields noninferior results vs intravenous isatuximab when paired with pomalidomide and dexamethasone in the phase 3 IRAKLIA trial.

Anito-cel produced no delayed or non–immune effector cell–associated neurotoxicity syndrome among patients with multiple myeloma.

Data Show Enduring Efficacy with Anito-cel in R/R Multiple Myeloma

Kristi Rosa
December 30th 2024
Article

Anito-cel produced no delayed or non–immune effector cell–associated neurotoxicity syndrome among patients with multiple myeloma.